CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
如何提高对适合 CAR-T 细胞治疗患者的成功识别？
英文原题：How can we improve the successful identification of patients suitable for CAR-T cell therapy?
查看英文原题
How can we improve the successful identification of patients suitable for CAR-T cell therapy?
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
我们回顾了 CAR-T 细胞疗法在最常见的血液系统恶性肿瘤中的当前可行性和挑战，并根据疾病类型和治疗优先级对其进行了分类，以指导临床医生和研究人员进一步应用和研究 CAR-T 细胞。
研究思路结论见上方概要
背景
近年来，CAR-T（CAR-T）细胞疗法在治疗难治性或复发性血液系统恶性肿瘤患者方面取得了突破性进展。然而，适合接受CAR-T 细胞治疗患者的识别方法仍有待改进。涵盖领域：CAR-T 细胞疗法在血液系统恶性肿瘤中已展现出卓越疗效；然而，在根据患者特征评估来决定何时应用CAR-T 细胞方面，观点仍存在争议。
展开英文摘要原文
INTRODUCTION: In recent years, chimeric antigen receptor T (CAR-T) cell therapy has resulted in a breakthrough in the treatment of patients with refractory or relapsed hematological malignancies.
However, the identification of patients suitable for CAR-T cell therapy needs to be improved. AREAS COVERED: CAR-T cell therapy has demonstrated excellent efficacy in hematological malignancies; however, views on determining when to apply CAR-T cells in terms of the evaluation of patient characteristics remain controversial.
EXPERT OPINION: We reviewed the current feasibility and challenges of CAR-T cell therapy in the most common hematological malignancies and classified them according to the disease type and treatment priority, to guide clinicians and researchers in applying and investigating CAR-T cells furtherly.
论文信息
- 作者
- Feng Y、Wu L、Gu T、Hu Y、Huang H
- 单位
- Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Expert review of molecular diagnostics2024 Sep
- 原文标识
- PubMed 39258858 · DOI 10.1080/14737159.2024.2399152